Pilot study puts injectable BOAS therapy on the radar

Version 1

A pilot study published in The Veterinary Journal reports early clinical improvement with Snoretox-1, an injectable neuromuscular stimulant, in six British bulldogs with brachycephalic obstructive airway syndrome, or BOAS. The therapy, developed by Snoretox Ltd. and researchers affiliated with RMIT University, uses a modified tetanus toxin designed to increase muscle tone in the floor of the mouth and help keep the upper airway open. According to the study and an RMIT release published April 23, 2026, all six dogs improved by at least one grade on the Respiratory Function Grading scale, with reported benefit lasting roughly 20 to 53 weeks. The study also included dogs that had ongoing signs after prior BOAS surgery, positioning the treatment as a possible adjunct or less-invasive alternative rather than a replacement for established care. (rmit.edu.au)

Why it matters: For veterinary professionals, the signal here is less about immediate practice change and more about a potentially new treatment category for a common, welfare-limiting condition. BOAS grading is already built around functional assessment before and after exercise, and grade II and III dogs generally require management and often treatment. If larger, controlled studies confirm these early findings, an injectable option could expand care for dogs that are poor surgical candidates, have persistent signs after surgery, or need multimodal management alongside weight control and airway procedures. The caveat is the evidence base is still very small, uncontrolled, and tied to a company-backed pilot study. (vet.cam.ac.uk)

What to watch: The next key milestone is a larger-scale trial and the regulatory path needed before Snoretox-1 could move beyond experimental use. (rmit.edu.au)